Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI

Cancer Immunology, Immunotherapy

Volumn 62, Issue 3, 2013, Pages 571-583

  Siegers, Gabrielle M ^a   Ribot, Emeline J ^a   Keating, Armand ^b   Foster, Paula J ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gamma delta T cell cytotoxicity; Gamma delta T cell expansion; Iron labeling; Preclinical cellular immunotherapy

Indexed keywords

CD27 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; CD69 ANTIGEN; FERUMOXYTOL; INTERLEUKIN 2; INTERLEUKIN 4; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; FERRIC ION; FERRIC OXIDE; LYMPHOCYTE ANTIGEN RECEPTOR; NANOPARTICLE;

ARTICLE; CANCER CELL; CELL CONTACT; CELL DENSITY; CELL EXPANSION; CELL KILLING; CELL LABELING; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ELECTRON MICROSCOPY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IRON TRANSPORT; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL NOISE RATIO; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; V DELTA 1 GAMMA DELTA T LYMPHOCYTE; V DELTA 2 GAMMA DELTA T LYMPHOCYTE; CELL SEPARATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; METHODOLOGY; STAINING; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SEPARATION; FERRIC COMPOUNDS; FERUMOXYTOL; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LYMPHOCYTE SUBSETS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; STAINING AND LABELING; T-LYMPHOCYTES, CYTOTOXIC;

MLCS; MLOWN;

EID: 84877141949     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1353-y     Document Type: Article

References (66)

1. Hayday AC (2000) [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18:975-1026 (Pubitemid 30365402)
2. Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67:5-8 (Pubitemid 46142752)
3. Lamb LS Jr, Lopez RD (2005) gammadelta T cells: a new frontier for immunotherapy? Biol Blood Marrow Transplant 11:161-168 (Pubitemid 40287914)
4. Ensslin AS, Formby B (1991) Comparison of cytolytic and proliferative activities of human gamma delta and alpha beta T cells from peripheral blood against various human tumor cell lines. J Natl Cancer Inst 83:1564-1569
5. Zheng BJ, Chan KW, Im S, Chua D, Sham JS et al (2001) Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int J Cancer 92:421-425 (Pubitemid 32249721)
6. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S et al (2008) Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother 31:313-323 (Pubitemid 351441003)
7. Knight A, Mackinnon S, Lowdell MW (2012) Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 14:1110-1118
8. Wright A, Lee JE, Link MP, Smith SD, Carroll W et al (1989) Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain. J Exp Med 169:1557-1564 (Pubitemid 19126815)
9. Freedman MS, D'Souza S, Antel JP (1997) gamma delta T-cell-human glial cell interactions. I. In vitro induction of gammadelta T-cell expansion by human glial cells. J Neuroimmunol 74:135-142 (Pubitemid 27128988)
10. Vollenweider I, Vrbka E, Fierz W, Groscurth P (1993) Heterogeneous binding and killing behaviour of human gamma/delta-TCR+ lymphokine-activated killer cells against K562 and Daudi cells. Cancer Immunol Immunother 36:331-336 (Pubitemid 23106003)
11. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP et al (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384-392 (Pubitemid 30463353)
12. Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y et al (2011) Human Vdelta1 gammadelta T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 13:753-764
13. Siegers GM, Felizardo TC, Mathieson AM, Kosaka Y, Wang XH et al (2011) Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model. PLoS ONE 6:e16700
14. Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G et al (2002) Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol 168:1484-1489 (Pubitemid 34094523)
15. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N et al (2003) Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 198:391-397 (Pubitemid 36980610)
16. Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD (2005) Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol 173:1552-1556 (Pubitemid 40524770)
17. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S et al (2007) Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67:7450-7457 (Pubitemid 47206575)
18. Yamaguchi T, Fujimiya Y, Suzuki Y, Katakura R, Ebina T (1997) A simple method for the propagation and purification of gamma delta T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. J Immunol Methods 205:19-28 (Pubitemid 27297830)
19. Yamaguchi T, Suzuki Y, Katakura R, Ebina T, Yokoyama J et al (1998) Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gammadeltaT cells isolated from glioblastoma patients. Cancer Immunol Immunother 47:97-103 (Pubitemid 28443560)
20. Fujimiya Y, Suzuki Y, Katakura R, Miyagi T, Yamaguchi T et al (1997) In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients. Clin Cancer Res 3:633-643 (Pubitemid 27211844)
21. Lamb LS Jr (2009) Gammadelta T cells as immune effectors against high-grade gliomas. Immunol Res 45:85-95
22. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H et al (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56:469-476 (Pubitemid 46204533)
23. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K (2010) Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 30:575-579
24. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T et al (2010) A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37:1191-1197
25. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I et al (2008) Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57:1599-1609
26. Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K et al (2011) Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105:778-786
27. Mallett CL, McFadden C, Chen Y, Foster PJ (2012) Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging. Cytotherapy 14:743-751
28. de Chickera S, Willert C, Mallet C, Foley R, Foster P et al (2012) Cellular MRI as a suitable, sensitive non-invasive modality for correlating in vivo migratory efficiencies of different dendritic cell populations with subsequent immunological outcomes. Int Immunol 24:29-41
29. Zhang X, de Chickera SN, Willert C, Economopoulos V, Noad J et al (2011) Cellular magnetic resonance imaging of monocyte-derived dendritic cell migration from healthy donors and cancer patients as assessed in a scid mouse model. Cytotherapy 13:1234-1248
30. Gonzalez-Lara LE, Xu X, Hofstetrova K, Pniak A, Chen Y et al (2010) The use of cellular magnetic resonance imaging to track the fate of iron-labeled multipotent stromal cells after direct transplantation in a mouse model of spinal cord injury. Mol Imaging Biol
31. Jirak D, Kriz J, Strzelecki M, Yang J, Hasilo C et al (2009) Monitoring the survival of islet transplants by MRI using a novel technique for their automated detection and quantification. MAGMA 22:257-265
32. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF et al (2006) In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 55:23-29 (Pubitemid 43062924)
33. Oweida AJ, Dunn EA, Karlik SJ, Dekaban GA, Foster PJ (2007) Iron-oxide labeling of hematogenous macrophages in a model of experimental autoimmune encephalomyelitis and the contribution to signal loss in fast imaging employing steady state acquisition (FIESTA) images. J Magn Reson Imaging 26:144-151 (Pubitemid 47235242)
34. Bernas LM, Foster PJ, Rutt BK (2010) Imaging iron-loaded mouse glioma tumors with bSSFP at 3 T. Magn Reson Med 64:23-31
35. Foster PJ, Dunn EA, Karl KE, Snir JA, Nycz CM et al (2008) Cellular magnetic resonance imaging: in vivo imaging of melanoma cells in lymph nodes of mice. Neoplasia 10:207-216 (Pubitemid 351328581)
36. Perera M, Ribot EJ, Percy DB, McFadden C, Simedrea C et al (2012) In vivo magnetic resonance imaging for investigating the development and distribution of experimental brain metastases due to breast cancer. Trans Oncol 5:217-225
37. Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM et al (2006) In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 56:1001-1010 (Pubitemid 44691342)
38. Ribot EJ, Foster PJ (2012) In vivo MRI discrimination between live and lysed iron-labeled cells using balanced steady state free precession. Eur Radiol (in press)
39. Garden OA, Reynolds PR, Yates J, Larkman DJ, Marelli-Berg FM et al (2006) A rapid method for labelling CD4+ T cells with ultrasmall paramagnetic iron oxide nanoparticles for magnetic resonance imaging that preserves proliferative, regulatory and migratory behaviour in vitro. J Immunol Methods 314:123-133 (Pubitemid 44219015)
40. Beer AJ, Holzapfel K, Neudorfer J, Piontek G, Settles M et al (2008) Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles. Eur Radiol 18:1087-1095
41. Iida H, Takayanagi K, Nakanishi T, Kume A, Muramatsu K et al (2008) Preparation of human immune effector T cells containing iron-oxide nanoparticles. Biotechnol Bioeng 101:1123-1128
42. Janic B, Rad AM, Jordan EK, Iskander AS, Ali MM et al (2009) Optimization and validation of FePro cell labeling method. PLoS ONE 4:e5873
43. Arbab AS, Janic B, Jafari-Khouzani K, Iskander AS, Kumar S et al (2010) Differentiation of glioma and radiation injury in rats using in vitro produce magnetically labeled cytotoxic T-cells and MRI. PLoS ONE 5:e9365
44. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D et al (2000) Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18:410-414 (Pubitemid 30217528)
45. Liu L, Ye Q, Wu Y, Hsieh WY, Chen CL et al (2012) Tracking T-cells in vivo with a new nano-sized MRI contrast agent. Nanomedicine [Epub ahead of print]
46. Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A (2001) Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 8:1131-1135 (Pubitemid 33035744)
47. Mallett CL, Foster PJ (2011) Optimization of the balanced steady state free precession (bSSFP) pulse sequence for magnetic resonance imaging of the mouse prostate at 3T. PLoS ONE 6:e18361
48. Lamb LS Jr, Musk P, Ye Z, van Rhee F, Geier SS et al (2001) Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant 27:601-606 (Pubitemid 32401457)
49. Halary F, Pitard V, Dlubek D, Krzysiek R, de la Salle H et al (2005) Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 201:1567-1578 (Pubitemid 40721002)
50. Schilbach K, Frommer K, Meier S, Handgretinger R, Eyrich M (2008) Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. J Immunother 31:896-905
51. Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O et al (2012) Antibody-dependent anti-cytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood 119:1418-1427
52. Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P et al (2010) The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 116:2164-2172
53. Dokouhaki P, Han M, Joe B, Li M, Johnston MR et al (2010) Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett 297:126-136
54. Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D et al (2011) Differentiation of human peripheral blood Vdelta1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118:992-1001
55. Poggi A, Zocchi MR, Carosio R, Ferrero E, Angelini DF et al (2002) Transendothelial migratory pathways of V delta 1+ TCR gamma delta+ and V delta 2+ TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II. J Immunol 168:6071-6077 (Pubitemid 34620022)
56. Janssen O, Wesselborg S, Heckl-Ostreicher B, Pechhold K, Bender A et al (1991) T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor gamma delta+ T cells. J Immunol 146:35-39
57. Lopez RD, Xu S, Guo B, Negrin RS, Waller EK (2000) CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 96:3827-3837
58. Viey E, Laplace C, Escudier B (2005) Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 5:973-986 (Pubitemid 43033787)
59. Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K et al (2008) Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10:842-856
60. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F et al (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102:200-206 (Pubitemid 36759655)
61. Pennington DJ, Silva-Santos B, Shires J, Theodoridis E, Pollitt C et al (2003) The inter-relatedness and interdependence of mouse T cell receptor gammadelta+ and alphabeta+ cells. Nat Immunol 4:991-998 (Pubitemid 37265920)
62. Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G et al (2005) Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol 35:1764-1772 (Pubitemid 40862324)
63. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH et al (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96:6879-6884 (Pubitemid 29274978)
64. Novotna B, Jendelova P, Kapcalova M, Rossner P Jr, Turnovcova K et al (2012) Oxidative damage to biological macromolecules in human bone marrow mesenchymal stromal cells labeled with various types of iron oxide nanoparticles. Toxicol Lett 210:53-63
65. Brekelmans P, van Soest P, Voerman J, Platenburg PP, Leenen PJ et al (1994) Transferrin receptor expression as a marker of immature cycling thymocytes in the mouse. Cell Immunol 159:331-339 (Pubitemid 24381061)
66. Keating A, Bernstein ID, Papayannopoulou T, Raskind W, Singer JW (1983) EM-2 and EM-3: two new Ph'+ myeloid cell lines. In: PA GDM (ed) Symposia on molecular and cellular biology, new series; UCLA. Alan R. Liss, New York, pp 513-520